Laboratorios Sanfer: Company Profile

Background

Laboratorios Sanfer, established in 1941, is a leading Mexican pharmaceutical company committed to enhancing public health through innovative and effective therapeutic solutions. With over 80 years of experience, Sanfer has developed a diverse portfolio encompassing prescription pharmaceuticals, over-the-counter (OTC) products, and animal health solutions. The company operates across 13 therapeutic classes, including Infectology, Cardiovascular, Metabolic Syndrome, Gynecology, Oncology, OTC Products, Veterinary Health, Central Nervous System, Gastroenterology, Biotechnology, Nephrology, Urology, Respiratory System, and Ophthalmology. Sanfer's mission is to improve people's quality of life by providing accessible and high-quality healthcare products.

Key Strategic Focus

Sanfer's strategic focus centers on:

• Therapeutic Diversification: Offering a comprehensive range of products across multiple therapeutic areas to address diverse medical needs.

• Geographical Expansion: Strengthening its presence in Latin America through strategic acquisitions and partnerships.

• Innovation and Quality: Investing in research and development to introduce innovative products and maintain high manufacturing standards.

• Sustainability and Social Responsibility: Committing to sustainable practices and contributing to community health initiatives.

Financials and Funding

In August 2019, Sanfer secured a significant investment of $500 million through a private equity round led by Caisse de dépôt et placement du Québec (CDPQ). This funding has been instrumental in supporting the company's expansion plans, including acquisitions and infrastructure development. The capital has been utilized to enhance production capabilities, expand market reach, and invest in research and development initiatives.

Pipeline Development

Sanfer's pipeline includes:

• Oncology: Developing biotechnological products targeting various cancers.

• Immunology: Focusing on treatments for autoimmune diseases.

• Chronic Degenerative Diseases: Creating therapies for conditions such as diabetes and metabolic disorders.

• Animal Health: Expanding its portfolio with vaccines and treatments for livestock and companion animals.

Technological Platform and Innovation

Sanfer distinguishes itself through:

• Proprietary Technologies: Utilizing advanced manufacturing processes to ensure product quality and efficacy.

• Scientific Methods: Employing cutting-edge research techniques, including biotechnological methods for drug development.

• AI-Driven Capabilities: Integrating artificial intelligence in research and development to accelerate product discovery and optimization.

Leadership Team

Sanfer's leadership comprises experienced professionals dedicated to the company's mission:

• José Miguel Guerrero Mouret: CEO, leading strategic initiatives and overseeing operations across Latin America.

• Marina de Gannes: Director of Marketing and Business Development, responsible for driving market expansion and partnerships.

• Zoila Pulla: Chief Financial Officer, managing financial strategies and investor relations.

• Alicia Lester: Head of Research and Development, overseeing innovation and product development.

• Vivienne Gomez Berlie: Director of Regulatory Affairs, ensuring compliance with international standards.

Leadership Changes

In January 2024, Sanfer expanded its portfolio by acquiring Vitalis, a Colombian manufacturer of injectable products. This strategic move aims to enhance Sanfer's presence in the injectable pharmaceuticals market and strengthen its position in Latin America.

Competitor Profile

Market Insights and Dynamics

The Latin American pharmaceutical market is experiencing growth, driven by increasing healthcare demands and expanding access to medical services. Key trends include:

• Generic Drug Utilization: Rising adoption of generic medications to reduce healthcare costs.

• Biotechnology Advancements: Growth in biopharmaceuticals, particularly in oncology and immunology.

• Regulatory Developments: Evolving regulations impacting market entry and product approval processes.

Competitor Analysis

Sanfer's primary competitors in the region include:

• Genomma Lab: Specializes in OTC and specialty drugs, holding a significant market share in Mexico.

• Silanes Laboratories: Focuses on generic diabetes and metabolic drugs, with a strong presence in Mexico.

• Rimsa: Known for its generic diabetes and metabolic drugs, emphasizing quality and affordability.

Strategic Collaborations and Partnerships

Sanfer has established several strategic partnerships to enhance its market position:

• Hanmi Pharmaceutical: In January 2026, Sanfer signed an exclusive distribution agreement with Hanmi Pharmaceutical to introduce efpeglenatide, a GLP-1 obesity therapy, and the Dapalon Family, a diabetes treatment portfolio, in Mexico.

• Onconic Therapeutics: Entered into a licensing agreement to distribute Jaqbo (zastaprazan), a GERD treatment, in 19 Latin American countries.

Operational Insights

Sanfer's operational strategy focuses on:

• Manufacturing Excellence: Maintaining state-of-the-art facilities in Mexico, Colombia, and Chile to ensure high-quality production.

• Supply Chain Optimization: Streamlining logistics to enhance distribution efficiency across Latin America.

• Regulatory Compliance: Adhering to international standards to facilitate market entry and product acceptance.

Strategic Opportunities and Future Directions

Sanfer is poised to capitalize on:

• Biotechnological Advancements: Expanding its biopharmaceutical portfolio to address complex medical conditions.

• Regional Expansion: Strengthening its presence in underpenetrated Latin American markets.

• Sustainability Initiatives: Implementing eco-friendly practices to align with global sustainability goals.